| Autor: |
Najafi, Ali, Ghanei, Mostafa, Janbabaei, Ghasem, Velayati, Ali Akbar, Saadat, Seyed Hassan, Jamaati, Hamidreza, Tabarsi, Payam, Dastan, Farzaneh, Ram, Malihe, Darabi, Enayat, Fathi, Saeid, Fesharaki, Mohammad Gholami, Ghazale, Amir Hosein, Saloo, Shahrzad |
| Předmět: |
|
| Zdroj: |
Tanaffos; 2020, Vol. 19 Issue 2, p112-121, 10p |
| Abstrakt: |
Background: The Coronavirus disease 2019 (COVID-19) outbreak quickly has spread and became a pandemic. However, no approved therapeutics or effective treatment is available for the treatment of these patients. The present study was done to retrospectively assess the treatment strategies (e.g., pharmaceutical care services) for COVID-19 patients in selected hospitals and highlight the importance of such services in the management of a pandemic. Materials and Methods: Data from a series of COVID-19 patients (978 patients; 658 males [66.9%] and 324 females [33.1%]) admitted to the selected hospitals in Tehran from 20 February to 19 March 2020 were retrieved retrospectively from the Health Information System (HIS) of the hospitals. The statistical tests were used for analyzing the effect and correlation of the variables (drugs) with the average length of stay (ALOS) in the hospital. Results: Diverse medication classes and old drugs with or without strong evidence of therapeutic effects against the novel coronavirus, some previously tried as a treatment for SARS-CoV and MERS-CoV, were mostly used for the treatment of patients in the hospitals. Many medications (broad-spectrum antibiotics and antivirals) or combination therapies are used without evidence of their therapeutic effects during pandemics. Conclusion: Therefore, guidelines should be provided for the off-label use of these drugs by policymakers and stakeholders during a pandemic emergency due to high demands. Also, monitoring of the HIS data can play an important role in improving public health response to emerging diseases. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
